Trulieve Cannabis (OTCMKTS:TCNNF) PT Raised to $19.00

Trulieve Cannabis (OTCMKTS:TCNNFGet Free Report) had its price objective raised by equities research analysts at Roth Mkm from $16.00 to $19.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Roth Mkm’s price objective suggests a potential upside of 63.79% from the stock’s previous close.

Separately, Needham & Company LLC increased their target price on shares of Trulieve Cannabis from $13.50 to $14.50 and gave the company a “buy” rating in a research report on Friday.

Get Our Latest Stock Analysis on Trulieve Cannabis

Trulieve Cannabis Price Performance

TCNNF stock opened at $11.60 on Friday. Trulieve Cannabis has a one year low of $3.42 and a one year high of $14.50. The firm has a 50-day simple moving average of $11.25 and a two-hundred day simple moving average of $8.27.

Trulieve Cannabis Company Profile

(Get Free Report)

Trulieve Cannabis Corp., together with its subsidiaries, operates as a cannabis retailer. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, creams, balms, salves, lotions, vaporizers, batteries, cartridge, concentrates, topicals, capsules, synringes, tinctures, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers, and Roll One brands.

See Also

Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.